Medical Doctor Program year 2024 Reported 2019–2024 Source: CMS Open Payments, 2026 publication

Apurv Agrawal

Hematology & Oncology Brick, NJ Medical Doctor

NPI 1639188766 CMS profile 345992

1608 Route 88 W, Suite 250, Brick, NJ 08724

Open in the dashboard

General payments

$16,584

60 records reported · program years 2019–2024

Research payments

$3,026

Paid to them · 6 records reported · program years 2019–2024

Ownership & investment interest

$0

None reported

Research they led as principal investigator

$817,517 paid to institutions, not to them · program years 2019–2025

Through program year 2024, Apurv Agrawal of Brick, NJ is reported in the CMS Open Payments database as having received $16,584 across 60 general payments and $3,026 in research payments paid to them. Separately, studies naming them as principal investigator received $817,517 in research payments, paid to institutions rather than to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them. The principal-investigator line is research money paid to institutions for studies they led — not to them — and is not added to anything either.

General payments for this record sit in the 80th percentile of Hematology & Oncology profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

8 rows
Year Kind Relative to this record's peak year Amount Records
2024 General $604 4
2023 General $4,634 14
2022 General $5,903 17
2021 General $1,831 13
2021 Research $16 1
2020 General $3,250 7
2019 General $363 5
2019 Research $3,010 5

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Apurv Agrawal
  • Hematology & Oncology median
  • Middle half of Hematology & Oncology
  • National median

In program year 2025, general payments to Apurv Agrawal were reported at $0. Among 8,769 Hematology & Oncology profiles paid that year, the median was $683 and the middle half received between $143 and $3,154.

Show as a table
Year Apurv Agrawal Hematology & Oncology median Middle half National median
2019 $363 $529 $121–$2,516 $163
2020 $3,250 $339 $82–$2,213 $114
2021 $1,831 $263 $49–$1,965 $132
2022 $5,903 $416 $103–$2,395 $149
2023 $4,634 $542 $125–$2,646 $160
2024 $604 $692 $141–$3,008 $164
2025 $0 $683 $143–$3,154 $169

Breakdown

Who paid General payments · program years 2019–2024
  1. CTI BioPharma Corp. $6,340 6 payments
  2. Janssen Biotech, Inc. $5,520 7 payments
  3. Celgene Corporation $3,087 3 payments
  4. MorphoSys, US Inc. $485 1 payment
  5. Asd Specialty Healthcare, LLC $218 1 payment
  6. Seattle Genetics, Inc. $126 2 payments
  7. E.R. Squibb & Sons, L.L.C. $124 6 payments
  8. Incyte Corporation $115 2 payments
  9. Boston Scientific Corporation $83 1 payment
  10. Novartis Pharmaceuticals Corporation $75 4 payments
  11. Other $412 27 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2024
  1. Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program $5,500 6 payments
  2. Consulting Fee $3,560 3 payments
  3. Honoraria $3,375 2 payments
  4. Compensation for serving as faculty or as a speaker for a medical education program $2,700 1 payment
  5. Food and Beverage $1,208 44 payments
  6. Education $210 3 payments
  7. Travel and Lodging $31 1 payment
Products named General payments · program years 2019–2024
  1. Vonjo $6,340 6 payments
  2. BALVERSA $3,300 3 payments
  3. RYBREVANT $1,670 3 payments
  4. INREBIC $1,663 1 payment
  5. REBLOZYL $1,413 1 payment
  6. MONJUVI $485 1 payment
  7. OPDIVO $107 5 payments
  8. SUPERION $83 1 payment
  9. SCEMBLIX $60 3 payments
  10. OGSIVEO $37 2 payments
  11. Other $535 34 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Research payments came from Research payments · program years 2019–2024
  1. Takeda Pharmaceuticals U.S.A., Inc. $3,010 5 payments
  2. Eli Lilly and Company $16 1 payment

Prescribing to Medicare patients

Part D · data year 2024 · 10 drugs

Part D claims

266

Median for Medical Oncology: 414

Drug cost

$421,326

Median for Medical Oncology: $849,427

Branded share of claims

31.6%

Median for Medical Oncology: 28.5%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Xtandi Enzalutamide Brand 16 $255,263
Jakafi Ruxolitinib Phosphate Brand 12 $135,709
Eliquis Apixaban Brand 41 $25,956
Letrozole Generic 50 $1,477
Hydroxyurea Generic 41 $1,177
Tamoxifen Citrate Generic 18 $722
Anastrozole Generic 11 $330
Oxycodone-Acetaminophen Oxycodone Hcl/Acetaminophen Brand 15 $308
Ondansetron Hcl Generic 35 $255
Prednisone Generic 27 $128

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 3,431 Part D prescribers listed as Medical Oncology; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 101 billing codes

Paid by Medicare

$896,466

Of which drugs: $797,202

Medicare patients

608

Average age 77

Services billed

64,390

312 women, 296 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Arthritis 56%
Diabetes 50%
Ischemic heart disease 49%
Cancer 45%
Chronic kidney disease 44%
COPD 36%
Atrial fibrillation 29%
Drugs given in the clinic that this provider billed Medicare Part B for
Drug given in the clinic Where Patients Services Paid by Medicare
Injection, pembrolizumab, 1 mg J9271 Office 13 6,600 $287,973
Injection, denosumab, 1 mg J0897 Office 22 2,700 $52,530
Injection, ferric carboxymaltose, 1 mg J1439 Office 18 15,750 $13,956
Injection, epoetin alfa, (for non-esrd use), 1000 units J0885 Office 17 1,250 $8,161
Injection, epoetin alfa, biosimilar, (retacrit) (for non-esrd use), 1000 units Q5106 Office 16 870 $4,719
Injection, granisetron hydrochloride, 100 mcg J1626 Office 22 530 $152
Injection, dexamethasone sodium phosphate, 1 mg J1100 Office 26 986 $88
Infusion, normal saline solution , 1000 cc J7030 Office 11 25 $52
Infusion, normal saline solution, sterile (500 ml = 1 unit) J7040 Office 11 30 $31
Injection, vitamin b-12 cyanocobalamin, up to 1000 mcg J3420 Office 13 26 $20

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

2 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
OGSIVEO
  • SpringWorks Therapeutics, Inc. $37
$37 — —
OJJAARA
  • GlaxoSmithKline, LLC. $17
$17 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

Records

66 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Hematology & Oncology in New Jersey

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2024

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record